Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 4416 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Shire suffers on J&J drug death worries

Johnson & Johnson Pharmaceutical R&D (J&JPRD)announced that health authorities are reviewing scientific data from two clinical trials evaluating an investigational use of Reminyl (galantamine hydrobromide) in individuals with

Peregrine brain cancer trial protocol approved

The protocol was approved by the protocol review committee of the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP). Peregrine and the New Approaches to Brain Tumor

Cipher to sell research services unit

The research services business will be sold to a group led by the current management team of Pharma Medica. Consideration will consist of a cash payment of $14

Pfizer to acquire private eye disease firm

The acquisition extends Pfizer’s research in the field of ophthalmology and will enable Angiosyn’s novel angiostatic agent to be further developed. The agent’s primary therapeutic indication is for